The overall objective of this contract is to assess the ability of AURAVAX therapeutics? (AURAVAX) novel mucosal adjuvant nanosting-002, together with influenza live attenuated virus (LAV) created…
Active Definitive Contract Awarded Last action
- Contract number
- 75A50124C00054
- Awardee
-
Auravax Therapeutics, Inc. UEI PAN3ZK2YLAL2
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $749,999
Award facts
- Opportunity
-
- 22100SOL00003 Solicitation number
- Contract value 100% obligated
- $749,999.00 Current and potential, with all options
- Completion date 74% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77009, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $749,999 |
About this award
The U.S. Department of Health and Human Services, through the Office of the Assistant Secretary for Preparedness and Response, awarded a $749,999 firm-fixed-price contract to Auravax Therapeutics, Inc. to assess the ability of Auravax's novel mucosal adjuvant NanoSting-002, together with influenza live attenuated virus (LAV) created with Codagenix's novel synthetic attenuated virus engineering technology. The contract has an ultimate completion date of December 31, 2026 and does not utilize any set-aside designation.
Description
The overall objective of this contract is to assess the ability of AURAVAX therapeutics? (AURAVAX) novel mucosal adjuvant nanosting-002, together with influenza live attenuated virus (LAV) created with codagenix novel synthetic attenuated virus engin
Quick answers
Who was awarded contract 75A50124C00054?
75A50124C00054 was awarded to Auravax Therapeutics, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 23, 2024.
How much is contract 75A50124C00054 worth?
The government has obligated $749,999 on 75A50124C00054.
Was contract 75A50124C00054 competed?
The extent of competition for 75A50124C00054 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award